

Overview of Albumin and Its Purification Methods

Ramin Raoufinia^{1,2}, Ali Mota², Neda Keyhanvar¹, Fatemeh Safari¹, Sara Shamekhi¹, Jalal Abdolalizadeh^{3,4*}

¹ Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

² Department of Clinical Biochemistry and Laboratory Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

³ Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

⁴ Paramedical faculty, Tabriz University of Medical Sciences, Tabriz, Iran.

Article info

Article History:

Received: 19 July 2016
Revised: 8 September 2016
Accepted: 10 September 2016
ePublished: 22 December 2016

Keywords:

- Human serum albumin
- Purification
- Chromatography
- Immunoaffinity

Abstract

As the most frequent plasma protein, albumin constitutes more than 50% of the serum proteins in healthy individuals. It has a key role in oncotic pressure maintenance and it is known as a versatile protein carrier for transportation of various endogenous and exogenous ligands. Reduced amounts of albumin in the body will lead to different kinds of diseases such as hypovolemia and hypoproteinemia. It also has various indications in shocks, burns, cardiopulmonary bypass, acute liver failure and etc. Further applications in research consist of cell culture supplement, drug delivery carrier and protein/drug stabilizer. So, the demand for albumin increased annually worldwide. Due to different applications of albumin, many efforts have been accomplished to achieve albumin during a long period of time. In this review, an overview of serum albumin and different purification methods are summarized.

Introduction

The name of albumin protein is taken from Albumen (etymologically goes back to Albus).¹ There exist different types of albumin, including ovalbumin, human serum albumin (HSA), and bovine serum albumin (BSA) which are described briefly in Table 1. Albumin is the most predominant circulating protein in healthy adults (normal physiological concentration is 0.6 Mm). It is synthesized in the liver and it causes 80% of plasma colloid osmotic pressure (COP). Since last century, due to critical physiological and biopharmaceutical function of albumin, efforts have been made to achieve high pure and qualified albumin in order to be utilized in therapeutic and research approaches. Human albumin has the highest demand among other biopharmaceutical solutions. Currently, the annual request of albumin is guessed approximately 500 metric tons in the world.² Till now various researchers and teams have tried to innovate new albumin production methods. Traditional techniques such as fractionation have been developed and currently diverse chromatographic techniques are used to attain albumin with high yield and purity. So, in the following review, different methods of albumin purification, production and cons and pros of each of them will be discussed.

Albumin Structure

Albumin is a single chain protein with low molecular weight (66/5 kDa) which containing 585 amino acids. It is a simple protein, non-glycosylated polypeptide, hydrophobic patches/cavities, and it lacks prosthetic

groups. Human albumin gene is located on chromosome 4 q (11-22) and mutations of this gene will end in anomalous protein. This gene has 1691 nucleotide and contains 14 introns and 15 exons.³⁻⁶ Albumin structure is composed of three domains which are homologous in structural features (this has been elucidated by using X-ray crystallography) (Figure 1).

The structure includes domains I in residues 1 to 195, domain II in residues 196 to 383 and domain III residues 384 to 585. Each domain consists of 2 identical subunits (A and B) and is composed of 4 and 6 α -helices consecutively. In X-ray crystallography, albumin was displayed as a heart-shaped tertiary in the human body and is containing 17 pairs of disulfide bridges. In the structure of albumin, there exists only one free cysteine (Cys34 is unpaired). Its approximate dimensions are of $80 \times 80 \times 30 \text{ \AA}$ and about 68% α -helix (any β -sheet).^{1,7}

Enzymatic properties

Human albumin has interesting enzymatic properties including: esterase activity, enolase activity, effects on eicosanoids, aryl acylamidase activity, stereospecificity, condensation reactions, binding and activation of drug conjugates. Also, some of enzymatic properties of albumin–ligand complexes are as follows: heme- and hemin–human albumin, human albumin and Buckminster fullerene, inactivation of reactive oxygen and nitrogen species, metalloenzymes constructed using albumin, lipid peroxide peroxidase activity and nanoparticles.⁸

*Corresponding author: Jalal Abdolalizadeh, Email: jabdolalizadeh@gmail.com

©2016 The Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.

Table 1. Types of albumin.

Albumin type	definition	M.W (Da)	pI	aa No.	applications	Cause of use
OVA	A highly functional food protein	47000	4.8	385	<ul style="list-style-type: none"> Carrier for drug delivery in food matrix design. Carrier for controlled drug release. 	<ul style="list-style-type: none"> low cost Availability Can form gel networks and stabilization of emulsions and foams.
HSA	The most common protein plasma	66438	5.9	585	<ul style="list-style-type: none"> Low blood volume compensation treatment of related diseases Drug delivery career Drug and sample stabilization Cell culture supplement 	<ul style="list-style-type: none"> Availability Biodegradability Lack of toxicity
BSA	The most common protein plasma	69323	4.7	585	<ul style="list-style-type: none"> Drug delivery Usage in pharmaceutical industry 	<ul style="list-style-type: none"> Medical importance Abundance Low cost Ease of purification Unusual ligand-binding properties

Abbreviations: **OVA**: Ovalbumin, **HSA**: Human serum albumin, **BSA**: Bovine serum albumin, **M.W**: Molecular weight, **Da**: Dalton, **pI**: isoelectric point, **aa No**: Amino acid number.




Figure 1. Albumin structure. Albumin protein is composed of three domains (elucidated by X-ray crystallography).

Albumin synthesis

Albumin synthesis occurs in hepatocyte cells, but isn't stored by the liver. Once produced, it is secreted into the portal circulation.⁹ The normal concentration of albumin is 3.5- 5 g/dl in healthy adults and 2.9- 5.5 g/dl in children. Nearly 35 percent of the total body albumin is exist in the intravascular compartment. The rate of synthesis is approximately 12-25 grams per day. Its biological half-life is approximately 19 days. Routinely albumin turnover occurred around 14 grams in a normal 70 kg adult which is approximately 50 percent in the muscles and skin.^{10,11} Among factors that modify albumin metabolism and leads to its reduced synthesis, can be noted to decreased gene transcription (such as trauma, sepsis, hepatic diseases, diabetes, decreased

growth hormone, decreased corticosteroids) and ribosome disaggregation (like protein depletion, fasting).¹²

Hypoalbuminemia, which is described as insufficient low levels of HSA in the blood is a common symptom of ill patients. This symptom is not only a result of reduction in albumin synthesis, but related to the breakdown, protein uptake and leakage to the extravascular space.^{13,14} These conditions are created in sub-conditions such as liver and kidney, infections, AIDS, lymphoma, cancer, poverty nutrition, surgery, burn damage, chemotherapy, spontaneous bacterial peritonitis, taking medication, prematurity infant, acute respiratory distress syndrome, chronic respiratory diseases, acute necrotizing, infant brain hemorrhage, hydrops fetalis, systemic inflammatory response syndrome, sepsis and infant edema. Moreover, it can be seen in intestinal diseases such as Castleman.¹⁵⁻²⁰

Functions

Albumin is known as a multifunctional plasma protein. It is the main regulator of plasma oncotic pressure. Beside this, any alteration in the oncotic pressure can lead to the stimulation of HSA synthesis. It can bind to different molecules due to its tertiary structure. Such molecules can include metabolites, gases or exogenous substances such as drugs. There has been no evidence about presence of HSA receptor besides only a receptor-mediated endocytosis mechanism is assumed for loaded HSA. It also acts as a chaperone molecule which helps promoting the folding of various proteins and prevents the formation of aggregated proteins related to diseases.^{8,21,22} Plasma, as a place which is exposed to different types of oxidative stresses, encompasses the HSA. This protein is well-known for its anti-oxidant activity that

encounters varieties of reactive oxygen species (ROS) and reactive nitrogen species (RNS). It also reduces the production chance of reactive species by binding to the major cause of free radical production, free Cu (II). This ability will make the HSA an oxido-redox biomarker.²³⁻²⁵ There exist other less-known properties of HSA such as anti-coagulant and anti-thrombotic functions. It also leads to delayed aggregation of platelets by binding to Nitric oxide (NO) and inhibiting its inactivation. Like other plasma proteins, HSA, due to its long half-life, is prone to glycation.²⁶ Glycated HSA will cause irreparable damages in different diseases. Studies also reported that HSA protects other proteins from glycation. HSA is also supposed to be responsible for membrane permeability. The hypothesis of mechanism is due to binding of HSA to subendothelium and interstitial layers and then altering their permeability. HSA is reported to have neuroprotective function on neuronal and glial cells and regulates brain circulation. Experimental ischemic and Alzheimer's disease model indicates HSA administration, which can play a neuroprotective and anti-oxidant role. This function is mainly related to anti-oxidant properties of HSA. In vitro studies on hepatocytes or liver microsomes of rats indicated that HSA is increased with aging only in male rats. In human, sex-related HSA amount is doubted but there is a fact that before age 14, plasma protein levels are sex-independent and the variation is only occur between ages 18-24. Moreover, HSA level decrease until human being reaches age 55 and after that, it is again age-independent.^{1,25,27-34}

Applications

Serum albumin is utilized under various clinical conditions. Restoration of blood volume, emergency treatment of shock, acute management of burns, and other situations associated with hypovolemia are some of the clinical applications of albumin. Knowing this, Serum albumin is a nobility biomarker for liver function synthesis, and also for several diseases, such as, inflammatory disorders, brain tumors, rheumatoid arthritis, myocardial ischemia, cancer, blood brain barrier (BBB) damage, kidney disease, cerebrovascular disease, cardiovascular risk disease, and also in disorders which requires the blood sugar control.³⁵⁻³⁹ In addition, albumin has different applications in the related research field, including cryopreservation, stabilizer of some of the proteins and as a supplement in cell culture. Novel application of HSA is consisted of a fusion of peptides, a drug nanocarrier and an oxygen transporter.^{2,11,40}

Therapeutic formats

Clinical indication of albumin is done in two forms. The first one is albumin 4-5% (near iso-oncotic solution) which leads to intravascular volume expansion, and the second one is albumin 20-25% (hyper oncotic solution) which is applied in the

restoration of COP and fluid balance preservation among compartments.⁴¹ Injection of these 5%, 20%, or 25% albumins is used for hypoalbuminemia treatment which is sterilized under $60 \pm 0.5^\circ\text{C}$ for 10–11 h to viral inactivation. This sterilization process is likely to induce denatured HSA.⁴²⁻⁴⁵

Indications

Clinical indications of albumin 4-5% solution includes emergency treatment of hypovolemic shock, cardiopulmonary bypass, acute liver failure, sequestration of protein rich fluids.^{46,47} Clinical indications of albumin 20-25% solution may include hypovolemia, hypoproteinemia, adult respiratory distress syndrome (ARDS), hemolytic disease of the newborn (HDN), acute nephrosis, acute liver failure, renal dialysis, hypovolemic shock, burn therapy, cardiopulmonary bypass, sequestration of protein rich fluids, and erythrocyte resuspension.⁴⁸

Contraindications

Although albumin is a valuable therapeutic product in a broad range of disorders, but its administration in some situations may be hazardous. Precede the prescription of albumin, its circulation amount should be checked, the level of more than 2.5 g/dl (hyperalbuminemia) cause contraindication. Cardiac and renal failures, acute or chronic pancreatitis, pulmonary edema or severe anemia because of the risk of acute circulatory overload are the other situations in which albumin is forbidden. In addition, utilization of albumin in patients with nervous system disorders such as cerebral ischemia and traumatic brain injury (TBI) may be dangerous and life threatening. Also, indication of albumin in conditions is not recommended such as ascites responsive to diuretics, non-hemorrhagic shock, hypoalbuminemia without the incidence of edema or acute hypotension, malnutrition, wound healing, acute normovolemic hemodilution in surgery, ascites responsive to diuretics, protein-losing enteropathies and malabsorption, acute normovolemic hemodilution in surgery.^{41,49-52}

Side effects

Along with the beneficial effects of albumin, it can have a variety of side effects when indicated intravenously. List of these side effects are noted in Table 2.^{53,54}

Table 2. Side effect of intravenous injection of human serum albumin.

Organ	Side effects
Dermatologic	Urticarial, skin rash, pruritus, edema, and erythema
Nervous system	Headache, chills, and febrile reactions
Gastrointestinal	Nausea, vomiting and increased salivation
Cardiovascular	Hypotension
Respiratory	Bronchospasm

Human albumin purification methods

Plasma fractionation method with ethyl alcohol

Approximately 60 years ago, Cohn and colleagues developed a protein purification method by using plasma fractionation technique for the first time. This approach is based on albumin solubility difference with other plasma proteins. Comparing to other plasma proteins, albumin sediments in lower pH and higher ethanol concentration. In this method there are five available systems for separation of plasma protein. The basic principles includes ethyl alcohol (8-40%), temperature (-3 to -10 °C), pH (4.5-7.2), protein concentration (5.1-8 %), and ionic strength (0.14-0.01).⁵⁵⁻⁵⁷ Protein separation is a result of the increase in ethyl alcohol concentration occurring in each fraction, so albumin will be seen in the last fraction. This method which is done under bacteriostatic condition, can be used as therapeutic agents. The method is suitable for large-scale and industrial production. But this method has some disadvantages, too; It is not enable to produce high purity product, protein denaturation may occur, and this method needs cold areas.⁵⁷

The Cohn method combined with chromatography

The Cohn method was modified by Oncley *et al.* in 1949 and Kistler-Nitschman *et al.* in 1962 in order to improve albumin purification.⁵⁸ It is shown in Figure 2.

The Cohn method combined with liquid chromatography

This method at first was described by Tanaka *et al.* Large volumes of plasma with low price is fractionated in Cohn method, so Victoria and colleagues to raise the purity and quality of the product, added liquid chromatography technique. Due to the benefits of both techniques, this method was considered as an integrated method for the purification of plasma proteins. Among advantages of this method one can point to the low cost and high purified albumin which leads to the promoted product quality. The purified product using the present method is yielded approximately 99% which is higher than Cohn's method. In this method albumin is a by-product and other important therapeutic proteins including factor VIII, intravenous immunoglobulin (IVIG) and some other proteins are isolated from plasma. This method is used for industrial production of plasma proteins in the world.⁵⁹

Purification from placenta

Another method which has been developed for production of albumin is purification from human placenta. Joaquin Cabrera-Crespo and colleagues described this method which was performed using solvent precipitation (with ethanol) and ion exchange chromatography. Since human placenta collection is

available, purification from placenta is one of the most efficient ways of purification of albumin. Among the advantages of the mentioned technique, one can point to the reduction in the volume of resin used in the chromatographic process in comparison with the isolation processes. They have acquired albumin of placenta with 97.1 percent purity.^{60,61}

Affinity precipitation (using a thermo-response polymer attach with an L-thyroxin ligand)

Currently, Cao and Ding reported affinity precipitation process for purification of plasma proteins (such as albumin). It is performed by using reversibly soluble-insoluble polymers combined with an affinity ligand which depends on the polymer features such as temperature, pH and light response. With using N-methylol acrylamide, butyl acrylate and N-isopropyl acrylamide as monomers, a thermo-response copolymer was synthesized which was called P_{NBN}. Then, L-thyroxin ligand, as an affinity ligand, was coupled to P_{NBN} and was used to purify albumin from human serum.⁶² One of the advantages of this new production method is tolerable purity HSA production in a single step.

Heat shock method

Since the albumin is stable in thermal fluctuation comparing to the other proteins of the plasma, it can be purified in heat shock purification method. So, albumin protein resists to increasing the temperature up to 60 °C in which potential pathogen may be inactivated. To obtain albumin from serum, 0.04 M caprylic acid was used to stabilize in pH 5 at 60 °C. In this state other proteins of the serum are denatured and precipitated in solution. Then albumin concentrated by precipitation and ultrafiltration with purity around 98 %.⁵⁷

Ammonium sulfate precipitation combined with liquid chromatography

Another method for albumin purification is ammonium sulfate precipitation combined with liquid chromatography which yields approximately more than 90 percent purified albumin. In this method albumin is separated from immunoglobulins by 50% ammonium sulfate. Then lipids are removed using ice-cold acetone (in 4 centigrade). In next stage for separating albumin from other proteins (especially transferrin which is the main contaminant), ion exchange and size exclusion chromatography are utilized. DNase and immune detection assays proved that the purified albumin was free of any DNases and immunoglobulins. Eventually, purified albumin was evaluated using western blotting and chemiluminescence.⁶³ Steps of the aforementioned method are shown in Figure 3.




Figure 2. The Cohn method combined with chromatographic techniques for purification of albumin. Abbreviations: **AT III:** Antithrombin III, **Ch:** Chromatography, **IEC:** Ion exchange chromatography, **α1-PI:** Alpha₁-Proteinase Inhibitor




Figure 3. Summary of Ammonium sulfate precipitation combined with liquid chromatography. Abbreviations: **IEC**: Ion exchange chromatography, **SXC**: Steric exclusion chromatography.

TCA/Acetone precipitation method

Although many low-abundant serum proteins play an important role in disease detection as a biomarker but some of them such as albumin which exists in high amount is an obstacle for detection. For better detection, we can eliminate albumin and enrich the serum for low-abundant proteins. In order to remove albumin from plasma for disease detection, Chen et al. developed a precipitation method using trichloroacetic acid (TCA)/acetone in 2005. They claim that their method can be a rapid and large scale albumin purification method. The albumin isolated by this method seemed to maintain its native structure beside other characteristics such as solubility, temperature stability, electrophoretic mobility, dye-binding properties, crystallization characteristics, and immunologic behavior.⁶⁴

Column chromatography for the purification of HSA

Although the ethyl alcohol fractionation method is used in industry for blood protein's fractionation, the purity is not sufficient enough.⁵⁷ So, chromatography might be the best choice for albumin and other protein's purification. To achieve this goal, there have been

variable chromatography techniques which some of their most predominant ones include.⁵⁷

Ion exchange chromatography (IEC)

IEC is widely used for albumin^{65,66} and other protein production.^{67,68} Among them the anion exchange method has the most usage.⁶⁶ Three steps of conventional method for IEC consisting pre-treatment, purification and polishing was shown in Figure 4. Some of the limitations of conventional methods for chromatography such as delayed processing time, low flow rates and etc. which are apparently known for everyone. To cope with these limitations, the new method for ion exchange membrane chromatography (IEM) using ameliorated adsorbers was developed. The simulation studies which compare the IEM with IEC were done by Frerick, et al.^{69,70} Comparing to column-based separations, the membrane chromatography has some advantages such as high separation efficiencies due to shorter diffusion times,⁷¹⁻⁷³ reduction in buffer usage, small floor space requirements,⁷⁴ simple method without complex hardware or packing necessities.⁷⁵ In spite of this advantages, expensive membrane and low efficiency of this technique for industrial purposes is an important drawback which causes the new technology

to be replaced.⁷⁶⁻⁷⁸ Moreover, membrane capacity to bind antibodies is relatively low in comparison with advanced resins.⁷⁸




Figure 4. Purification and polishing methods for human serum albumin (HSA). The purification process consists of two anion and cation exchange chromatography steps. The polishing process also consists of three steps containing two ultrafiltration and one gel filtration steps.

Simulated moving bed chromatography (SMB)

This is a multi-column method based on reversed-phase chromatography in which the sorbent and solvent consumption is decreased. Among the advantages of this method, increased efficiency (due to the countercurrent between solid and liquid phases), higher purity and yielding amount are the most outstanding. Nevertheless it has two disadvantages; on one hand the number of fractions is not more than two and each product stream contains more than one compound. On the other hand, the limitation of isocratic elution mode is a major problem. To overcome this problem, the pressure, pH and other factors can be modified. This four sectioned method is a promoted form of the "triangle method" by Storti et al.⁷⁹

Steric exclusion chromatography (SXC)

The new method for purification of large proteins is the steric exclusion chromatography (SXC) method which is based on PEG-induced precipitation and it is made using crogel monolith column. The polyethylene glycol (PEG) in the mobile phase helps proteins to restrain on the hydrophilic stationary phase. In 2014, Wang et al. reported that the crogels are very useful for protein separation. The advantage of cryogel monolith column compared to polymethacrylate monoliths is having the

large pores of approximately 10-100 μm which leads to a high flow rate along with low back pressure. Moreover, the retention capacity is supposed to be higher than adsorption-based chromatography. They could purify albumin and also globulin with high purity from bovine serum sample.⁸⁰

Expanded bed adsorption chromatography

The traditional fractionation process of plasma (the Cohn's cold ethanol method) is an isolating method for crucial plasma components. In 2009, Lihme et al. developed a new fractionation process containing five expanded bed adsorption steps using high-density modified agarose/tungsten carbide beads. Through this method, albumin was purified up to 99% purity following a recovery step using 6% agarose-10% tungsten carbide beads coupled with an acidic mixed-mode ligand under the acidic condition (pH 4.5). The EBA chromatography method might be an applicable alternative for core plasma fractionation method.⁸¹

Affinity Chromatography

Affinity chromatography is a type of liquid chromatography in which, a biological agent named affinity ligand is used as stationary phase in column. The purpose of this method is to selectively purify analytes and inspect the biological interactions between molecules.⁸²⁻⁸⁵ Affinity chromatography was first introduced for the purpose of purification by Cuatrecasas, et al. in 1968.⁸⁶ There are different types of affinity ligands such as protein, enzyme, enzyme substrate or inhibitor, antibody, antigen, hormone, biomimetic dye and etc. Depending on the purpose, selected type of ligand is immobilized within the column and further purification process is done following selective binding.⁸² Here we describe some:

Dye ligand affinity chromatography

Another important protein purification method is dye-ligand affinity chromatography. The biomimetic monochloro or dichlorotriazinyl dyes are able to bind most type of proteins, especially enzymes.^{87,88} It has so many advantages over other methods.⁸⁹ This method is economically and widely available and its immobilization and scale up is easy. Beside its medium specificity, the capacity is very high. Moreover, the matrix can be stored without losing its activity.⁹⁰ General dyes used in dye-ligand affinity chromatography can be noted to Reactive Red 120, CB F3GA, Congo Red, R. Green HE4BD, Reactive Blue 4, and Mimetic Blue 1 A6XL.^{57,91-111}

Immobilized Metal-ion Affinity Chromatography (IMAC)

In 2001, Denizli, et al. developed a novel and new method of purification to increase the protein adsorption capacity. They used the PHEMA beads containing 2-methacryloamidohistidine in metal chelate affinity chromatography. This survey indicated a

noteworthy growth in the HSA adsorption capacities from human plasma (up to 94.6 mg/g). Moreover, High desorption ratios (up to 98% of the adsorbed HSA) were noted. It was possible to reuse Cu (II) chelated (HEMA-co-MAH) beads without significant decreases in the adsorption capabilities.¹¹²

Boronate Affinity Chromatography

Boronate as an affinity ligand is used for affinity chromatography for separation. Targets, like carbohydrate-containing compounds, which have cis-diol groups, can bind to the boronate at a basic pH.⁸² Synthetic dyes are also used as ligands and the method is known as dye-ligand affinity chromatography. For this purpose, triazine dyes are used in columns to purify albumin and various proteins.^{113,114}

Immunoaffinity chromatography (IAC)

We applied IAC through Cyanogen bromide (CNBr) - activated Sepharose to facilitate albumin purification and improving its purity. Initially, the pure HSA was injected to the three white New Zealand rabbits to

produce of polyclonal antibody. Antibody purification was done by IEC and protein G affinity chromatography. Then the purified antibody was attached to the CNBr-activated Sepharose and eventually it used for purification of albumin protein from human serum. Western blotting analysis and heat-induced insolubility were applied for functional and stability assessment of immunoaffinity purified HSA, respectively.¹¹

IAC is mentioned as a robust method for albumin purification while joining with appropriate matrix. CNBr may be a most proper matrices for protein purification due to working as an activation reagent. We produced HSA with a purity of 98% through CNBr-activated sepharose. The purity of prepared albumin was high and no more differences was shown in heat-induced insolubility at 60-90 °C between purified and commercial albumin. Also IAC is a cost-effective and monophasic technique which could be a preferred method for plasma proteins purification.¹¹ Albumin purification methods was summarized in Table 3.

Table 3. Comparison of various methods for albumin production.

Method	Purity (%)	Advantage	Disadvantage	Clinical usage	Large-scale	R
Plasma Fractionation	96	Low cost, Its accessibility, Bacteriostatic nature of process, Ethanol is accessible and inexpensive, Safety of therapeutic product	Protein denaturation, Need raw material with high quality, Need to refrigerated tanks	✓	✓	57
Cohn+ LC	99	Low cost, Quality of manufactured product is superior of Cohn method, High purity, High yield, Safety of therapeutic product	Possibility of protein denaturation and/or aggregation during the addition of ethanol	✓	✓	59
Placenta	97.1	Reduction in the volume of resin used in the chromatographic process, High purity	The yield of product might be lower compared to other method, Difficulties in ensuring donor traceability, Contains a high concentration of a heat-stable alkaline phosphatase, Restriction in blood supply	✓	✓	61
Affinity Precipitation	93.6	Tolerable purity, Single step	Protein denaturation	✗	✗	62
Heat Shock	98	High purity	Protein denaturation	✓	✓	57
Ammonium sulfate+ LC	N/A	Sufficient purity, Suitable for major laboratory approach, Yield of albumin : ≤ 40 g/liter of serum	Not suitable for major clinical approach	✗	✓	63
IEC	≤ 95	High yield, Adsorption capacity is high, Better reproducibility, High recovery, Convenient for large-scale production	High media, Capital costs and Ligand leakage, Interactions between albumin and the ion exchange sorbents, Slow separation	✓	✓	66
SMB	96	Increased efficiency Higher purity and yield	Higher complexity, Higher maintenance costs	✗	✗	79
Dye Ligand affinity chromatography	≈ 98	Higher purity and yield, Quick separation, Medium specificity	Adsorption capacity is low, Elution condition is harsh, Incomplete regeneration	✗	✗	87

Abbreviations: **LC**: liquid chromatography, **IEC**: Ion exchange chromatography, **SMB**: Simulated moving bed chromatography, **CH**: Chromatography, **N/A**: not available.

Conclusion

Regarding to albumin protein priority, different methods were applied for albumin purification; Cohn method which combined with chromatographic

techniques is the most well-known among them. In this method other worthwhile proteins of plasma such as coagulation factors, immunoglobulins and etc. would be separated in upstream, and albumin will be seen in

the last fraction. Due to the robustness and high purity of plasma in large volumes, this technique, is cost-effective for plasma therapeutic protein production. Hence, this method currently seems to be a major technique in albumin production. The aforementioned methods such as purification from placenta, ammonium sulfate precipitation combined with LC, Heat shock, TCA/Acetone precipitation, different dye ligand affinity chromatographies, Simulated moving bed chromatography, Steric exclusion chromatography, Expanded bed adsorption chromatography and etc for albumin purification are suitable for lab-scale and don't have enough efficacy.

As respects, the raw material of these techniques is human serum with related safety limitation. Therefore efforts have been done to produce albumin via recombination technology.

Ethical Issues

Not applicable.

Conflict of Interest

The Authors report no declaration of interest.

References

- Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: From bench to bedside. *Mol Aspects Med* 2012;33(3):209-90. doi: 10.1016/j.mam.2011.12.002
- Chen Z, He Y, Shi B, Yang D. Human serum albumin from recombinant DNA technology: Challenges and strategies. *Biochim Biophys Acta* 2013;1830(12):5515-25. doi: 10.1016/j.bbagen.2013.04.037
- Ascenzi P, Fasano M. Allosteric in a monomeric protein: The case of human serum albumin. *Biophys Chem* 2010;148(1-3):16-22. doi: 10.1016/j.bpc.2010.03.001
- Hirose M, Tachibana A, Tanabe T. Recombinant human serum albumin hydrogel as a novel drug delivery vehicle. *Mater Sci Eng C* 2010;30(5):664-9. doi: 10.1016/j.msec.2010.02.020
- Curry S. Lessons from the crystallographic analysis of small molecule binding to human serum albumin. *Drug Metab Pharmacokinet* 2009;24(4):342-57. doi: 10.2133/dmpk.24.342
- Varshney A, Sen P, Ahmad E, Rehan M, Subbarao N, Khan RH. Ligand binding strategies of human serum albumin: How can the cargo be utilized? *Chirality* 2010;22(1):77-87.
- Caraceni P, Domenicali M, Tovoli A, Napoli L, Ricci CS, Tufoni M, et al. Clinical indications for the albumin use: Still a controversial issue. *Eur J Intern Med* 2013;24(8):721-8. doi: 10.1016/j.ejim.2013.05.015
- Kragh-Hansen U. Molecular and practical aspects of the enzymatic properties of human serum albumin and of albumin-ligand complexes. *Biochim Biophys Acta* 2013;1830(12):5535-44. doi: 10.1016/j.bbagen.2013.03.015
- Quinlan GJ, Martin GS, Evans TW. Albumin: Biochemical properties and therapeutic potential. *Hepatology* 2005;41(6):1211-9. doi: 10.1002/hep.20720
- Farrugia A. Albumin usage in clinical medicine: Tradition or therapeutic? *Transfus Med Rev* 2010;24(1):53-63. doi: 10.1016/j.tmr.2009.09.005
- Raoufinia R, Mota A, Nozari S, Aghebati Maleki L, Balkani S, Abdolalizadeh J. A methodological approach for purification and characterization of human serum albumin. *J Immunoassay Immunochem* 2016;37(6):623-35. doi: 10.1080/15321819.2016.1184163
- Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. *Br J Anaesth* 2000;85(4):599-610.
- Ballmer PE. Causes and mechanisms of hypoalbuminaemia. *Clin Nutr* 2001;20(3):271-3. doi: 10.1054/clnu.2001.0439
- Lee E, Eom JE, Jeon KH, Kim TH, Kim E, Jhon GJ, et al. Evaluation of albumin structural modifications through cobalt-albumin binding (CAB) assay. *J Pharm Biomed Anal* 2014;91:17-23. doi: 10.1016/j.jpba.2013.12.003
- Fritz HG, Brandes H, Bredle DL, Bitterlich A, Vollandt R, Specht M, et al. Post-operative hypoalbuminaemia and procalcitonin elevation for prediction of outcome in cardiopulmonary bypass surgery. *Acta Anaesthesiol Scand* 2003;47(10):1276-83.
- Safe Study Investigators, Finfer S, Bellomo R, McEvoy S, Lo SK, Myburgh J, et al. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: Analysis of data from the saline versus albumin fluid evaluation (safe) study. *BMJ* 2006;333(7577):1044. doi: 10.1136/bmj.38985.398704.7C
- Eljaiek R, Dubois MJ. Hypoalbuminemia in the first 24 h of admission is associated with organ dysfunction in burned patients. *Burns* 2013;39(1):113-8. doi: 10.1016/j.burns.2012.05.008
- Ryan AM, Hearty A, Prichard RS, Cunningham A, Rowley SP, Reynolds JV. Association of hypoalbuminemia on the first postoperative day and complications following esophagectomy. *J Gastrointest Surg* 2007;11(10):1355-60. doi: 10.1007/s11605-007-0223-y
- Kobayashi N, Nagai H, Yasuda Y, Kanazawa K. The early influence of albumin administration on protein metabolism and wound healing in burned rats. *Wound Repair Regen* 2004;12(1):109-14. doi: 10.1111/j.1067-1927.2004.012118.x
- Vlahos AL, Crawford RS, Matthew HT, Ledgerwood AM, Lucas CE. Effect of albumin

- and hespan on rodent hepatocyte function after hemorrhagic shock and sepsis. *J Trauma* 2005;59(3):583-8.
21. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. *J Control Release* 2012;157(2):168-82. doi: 10.1016/j.jconrel.2011.07.031
 22. Sleep D. Albumin and its application in drug delivery. *Expert Opin Drug Deliv* 2015;12(5):793-812. doi: 10.1517/17425247.2015.993313
 23. Taverna M, Marie AL, Mira JP, Guidet B. Specific antioxidant properties of human serum albumin. *Ann Intensive Care* 2013;3(1):4. doi: 10.1186/2110-5820-3-4
 24. Garcia-Martinez R, Andreola F, Mehta G, Poulton K, Oria M, Jover M, et al. Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure. *J Hepatol* 2015;62(4):799-806. doi: 10.1016/j.jhep.2014.10.031
 25. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. *FEBS Lett* 2008;582(13):1783-7. doi: 10.1016/j.febslet.2008.04.057
 26. Arasteh A, Farahi S, Habibi-Rezaei M, Moosavi-Movahedi AA. Glycated albumin: An overview of the in vitro models of an in vivo potential disease marker. *J Diabetes Metab Disord* 2014;13:49. doi: 10.1186/2251-6581-13-49
 27. Vincent JL, Sakr Y, Reinhart K, Sprung CL, Gerlach H, Ranieri VM, et al. Is albumin administration in the acutely ill associated with increased mortality? Results of the soap study. *Crit Care* 2005;9(6):R745-54. doi: 10.1186/cc3895
 28. Wratten ML, Sereni L, Tetta C. Oxidation of albumin is enhanced in the presence of uremic toxins. *Renal Fail* 2001;23(3-4):563-71. doi: 10.1081/Jdi-100104738
 29. Yamasaki K, Chuang VT, Maruyama T, Otagiri M. Albumin-drug interaction and its clinical implication. *Biochim Biophys Acta* 2013;1830(12):5435-43. doi: 10.1016/j.bbagen.2013.05.005
 30. Aubin E, Roberge C, Lemieux R, Bazin R. Immunomodulatory effects of therapeutic preparations of human albumin. *Vox Sang* 2011;101(2):131-7. doi: 10.1111/j.1423-0410.2011.01475.x
 31. Watanabe H, Tanase S, Nakajou K, Maruyama T, Kragh-Hansen U, Otagiri M. Role of Arg-410 and Tyr-411 in human serum albumin for ligand binding and esterase-like activity. *Biochem J* 2000;349(3):813-9. doi: 10.1042/bj3490813
 32. Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: Effect of anemia and erythropoietin injection. *J Am Soc Nephrol* 2007;18(3):896-903. doi: 10.1681/ASN.2006070772
 33. Kurono Y, Kushida I, Tanaka H, Ikeda K. Esterase-like activity of human serum albumin. VIII. Reaction with amino acid p-nitrophenyl esters. *Chem Pharm Bull (Tokyo)* 1992;40(8):2169-72.
 34. More J, Bulmer M. Human serum albumin: A multifunctional plasma protein. In: Bertolini J, Goss N, Curling J, editors. Production of plasma proteins for therapeutic use. New Jersey: Wiley; 2012. P. 159-83.
 35. Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. *Nutr J* 2010;9:69. doi: 10.1186/1475-2891-9-69
 36. Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. *Clin Chem* 2005;51(5):810-24. doi: 10.1373/clinchem.2004.046292
 37. Tibbling G, Link H, Ohman S. Principles of albumin and igg analyses in neurological disorders. I. Establishment of reference values. *Scand J Clin Lab Invest* 1977;37(5):385-90. doi: 10.1080/00365517709091496
 38. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. *Kidney Int* 2008;73(4):391-8. doi: 10.1038/sj.ki.5002585
 39. Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Svennerholm L. Blood-brain barrier disturbance in patients with alzheimer's disease is related to vascular factors. *Acta Neurol Scand* 1990;81(4):323-6.
 40. He Y, Ning T, Xie T, Qiu Q, Zhang L, Sun Y, et al. Large-scale production of functional human serum albumin from transgenic rice seeds. *Proc Natl Acad Sci U S A* 2011;108(47):19078-83. doi: 10.1073/pnas.1109736108
 41. Liunbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossettias G. Recommendations for the use of albumin and immunoglobulins. *Blood Transfus* 2009;7(3):216-34. doi: 10.2450/2009.0094-09
 42. Kragh-Hansen U, Watanabe H, Nakajou K, Iwao Y, Otagiri M. Chain length-dependent binding of fatty acid anions to human serum albumin studied by site-directed mutagenesis. *J Mol Biol* 2006;363(3):702-12. doi: 10.1016/j.jmb.2006.08.056
 43. Dugaiczuk A, Law SW, Dennison OE. Nucleotide sequence and the encoded amino acids of human serum albumin mrna. *Proc Natl Acad Sci U S A* 1982;79(1):71-5.

44. Gerety RJ, Aronson DL. Plasma derivatives and viral hepatitis. *Transfusion* 1982;22(5):347-51.
45. Fanali G, Ascenzi P, Fasano M. Effect of prototypic drugs ibuprofen and warfarin on global chaotropic unfolding of human serum heme-albumin: A fast-field-cycling 1h-nmr relaxometric study. *Biophys Chem* 2007;129(1):29-35. doi: 10.1016/j.bpc.2007.05.002
46. Tullis JL. Albumin: 1. Background and Use. *JAMA* 1977;237(4):355. doi: 10.1001/jama.1977.03270310039005
47. Clowes GH Jr, Vucinic M, Weidner MG. Circulatory and metabolic alterations associated with survival or death in peritonitis: Clinical analysis of 25 cases. *Ann Surg* 1966;163(6):866-85.
48. Boldt J. Use of albumin: An update. *Br J Anaesth* 2010;104(3):276-84. doi: 10.1093/bja/aep393
49. Martelli A, Strada P, Cagliani I, Brambilla G. Guidelines for the clinical use of albumin: Comparison of use in two italian hospitals and a third hospital without guidelines. *Curr Ther Res Clin Exp* 2003;64(9):676-84. doi: 10.1016/j.curtheres.2003.11.002
50. Vermeulen LC Jr, Ratko TA, Erstad BL, Brecher ME, Matuszewski KA. A paradigm for consensus. The university hospital consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. *Arch Intern Med* 1995;155(4):373-9.
51. Tarin Remohi MJ, Sanchez Arcos A, Santos Ramos B, Bautista Paloma J, Guerrero Aznar MD. Costs related to inappropriate use of albumin in Spain. *Ann Pharmacother* 2000;34(10):1198-205. doi: 10.1345/aph.19385
52. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *N Engl J Med* 2004;350(22):2247-56. doi: 10.1056/NEJMoa040232
53. Clark WG, Brater DC, Johnson AR. *Goth's medical pharmacology*. 13th ed. St Louis: Mosby; 1992.
54. Zhou T, Lu S, Liu X, Zhang Y, Xu F. Review of the rational use and adverse reactions to human serum albumin in the people's republic of China. *Patient Prefer Adherence* 2013;7:1207-12. doi: 10.2147/ppa.s53484
55. Cohn EJ, Strong LE, Hughes WL, Mulford DJ, Ashworth JN, Melin M, et al. Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. *J Am Chem Soc* 1946;68:459-75. doi: 10.1021/ja01207a034
56. Buchacher A, Iberer G. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety. *Biotechnol J* 2006;1(2):148-63. doi: 10.1002/biot.200500037
57. Denizli A. Plasma fractionation: Conventional and chromatographic methods for albumin purification. *Hacettepe J Biol Chem* 2011;39(4):315-41.
58. Johnston A, Adcock W. The use of chromatography to manufacture purer and safer plasma products. *Biotechnol Genet Eng Rev* 2000;17:37-70. doi: 10.1080/02648725.2000.10647987
59. Tanaka K, Shigueoka EM, Sawatani E, Dias GA, Arashiro F, Campos TC, et al. Purification of human albumin by the combination of the method of Cohn with liquid chromatography. *Braz J Med Biol Res* 1998;31(11):1383-8.
60. Cabrera-Crespo J, Goncalves VM, Martins EA, Grellet S, Lopes AP, Raw I. Albumin purification from human placenta. *Biotechnol Appl Biochem* 2000;31(2):101-6.
61. Grellet S, Martins EA, Maimoni Goncalves V, Yague Lopes AP, Raw I, Cabrera-Crespo J. An associated process for the purification of immunoglobulin G, catalase, superoxide dismutase and albumin from haemolysed human placenta blood. *Biotechnol Appl Biochem* 2001;34(Pt 3):135-42.
62. Ding Z, Cao X. Affinity precipitation of human serum albumin using a thermo-response polymer with an L-thyroxin ligand. *BMC Biotechnol* 2013;13:109. doi: 10.1186/1472-6750-13-109
63. Odunuga OO, Shazhko A. Ammonium sulfate precipitation combined with liquid chromatography is sufficient for purification of bovine serum albumin that is suitable for most routine laboratory applications. *Biochemical Compounds* 2013;1(1):3. doi: 10.7243/2052-9341-1-3
64. Chen YY, Lin SY, Yeh YY, Hsiao HH, Wu CY, Chen ST, et al. A modified protein precipitation procedure for efficient removal of albumin from serum. *Electrophoresis* 2005;26(11):2117-27. doi: 10.1002/elps.200410381
65. Kovacs A, Guttman A. Medicinal chemistry meets proteomics: Fractionation of the human plasma proteome. *Curr Med Chem* 2013;20(4):483-90.
66. Vasileva R, Jakab M, Hasko F. Application of ion-exchange chromatography for the production of human albumin. *J Chromatogr* 1981;216:279-84.
67. Abdolalizadeh J, Majidi J, Farajnia S. Production and purification of polyclonal antibody against human kappa light chain. *J Biol Sci* 2008;8(3):683-6. doi: 10.3923/jbs.2008.683.686
68. Aghebati Maleki L, Majidi J, Baradaran B, Abdolalizadeh J, Kazemi T, Aghebati Maleki A, et al. Large scale generation and characterization of anti-human CD34 monoclonal antibody in ascetic fluid of Balb/c mice. *Adv Pharm Bull* 2013;3(1):211-6. doi: 10.5681/apb.2013.035
69. Frerick C, Kreis P, Gorak A, Melzner D. Simulation and optimisation of the downstream process for purification of human serum albumin by using ion exchange membrane adsorbers. *Desalination*

- 2006;200(1-3):468-9. doi: 10.1016/j.desal.2006.03.398
70. Frerick C, Kreis P, Gorak A, Tappe A, Melzner D. Simulation of a human serum albumin downstream process incorporating ion-exchange membrane adsorbers. *Chem Eng Process* 2008;47(7):1128-38. doi: 10.1016/j.cep.2007.07.013
71. Reif OW, Freitag R. Characterization and application of strong ion-exchange membrane adsorbers as stationary phases in high-performance liquid chromatography of proteins. *J Chromatogr A* 1993;654(1):29-41. doi: 10.1016/0021-9673(93)83062-W
72. Tennikova TB, Svec F. High-performance membrane chromatography: Highly efficient separation method for proteins in ion-exchange, hydrophobic interaction and reversed-phase modes. *J Chromatogr A* 1993;646(2):279-88. doi: 10.1016/0021-9673(93)83340-X
73. Camperi SA, Navarro del Canizo AA, Wolman FJ, Smolko EE, Cascone O, Grasselli M. Protein adsorption onto tentacle cation-exchange hollow-fiber membranes. *Biotechnol Prog* 1999;15(3):500-5. doi: 10.1021/bp990054g
74. Phillips M, Cormier J, Ferrence J, Dowd C, Kiss R, Lutz H, et al. Performance of a membrane adsorber for trace impurity removal in biotechnology manufacturing. *J Chromatogr A* 2005;1078(1-2):74-82.
75. Boi C. Membrane adsorbers as purification tools for monoclonal antibody purification. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007;848(1):19-27. doi: 10.1016/j.jchromb.2006.08.044
76. Charcosset C. Membrane processes in biotechnology: An overview. *Biotechnol Adv* 2006;24(5):482-92. doi: 10.1016/j.biotechadv.2006.03.002
77. Low D, O'Leary R, Pujar NS. Future of antibody purification. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007;848(1):48-63. doi: 10.1016/j.jchromb.2006.10.033
78. Knudsen HL, Fahrner RL, Xu Y, Norling LA, Blank GS. Membrane ion-exchange chromatography for process-scale antibody purification. *J Chromatogr A* 2001;907(1-2):145-54.
79. Imamoglu S. Simulated moving bed chromatography (smb) for application in bioseparation. *Adv Biochem Eng Biotechnol* 2002;76:211-31.
80. Wang C, Bai S, Tao SP, Sun Y. Evaluation of steric exclusion chromatography on cryogel column for the separation of serum proteins. *J Chromatogr A* 2014;1333:54-9. doi: 10.1016/j.chroma.2014.01.059
81. Lihme A, Hansen MB, Andersen IV, Burnouf T. A novel core fractionation process of human plasma by expanded bed adsorption chromatography. *Anal Biochem* 2010;399(1):102-9. doi: 10.1016/j.ab.2009.12.002
82. Hage DS, Anguizola JA, Bi C, Li R, Matsuda R, Papastavros E, et al. Pharmaceutical and biomedical applications of affinity chromatography: Recent trends and developments. *J Pharm Biomed Anal* 2012;69:93-105. doi: 10.1016/j.jpba.2012.01.004
83. Abdolalizadeh J, Nouri M, Zolbanin JM, Barzegari A, Baradaran B, Barar J, et al. Targeting cytokines: Production and characterization of anti-TNF-alpha scFvs by phage display technology. *Curr Pharm Des* 2013;19(15):2839-47.
84. Abdolalizadeh J, Majidi Zolbanin J, Nouri M, Baradaran B, Movassaghpour A, Farajnia S, et al. Affinity purification of tumor necrosis factor-alpha expressed in raji cells by produced scFv antibody coupled CNBr-activated sepharose. *Adv Pharm Bull* 2013;3(1):19-23. doi: 10.5681/apb.2013.004
85. Abdolalizadeh J, Nouri M, Zolbanin JM, Baradaran B, Barzegari A, Omidi Y. Downstream characterization of anti-TNF-alpha single chain variable fragment antibodies. *Hum Antibodies* 2012;21(1-2):41-8. doi: 10.3233/HAB-2012-0260
86. Cuatrecasas P, Wilchek M, Anfinsen CB. Selective enzyme purification by affinity chromatography. *Proc Natl Acad Sci U S A* 1968;61(2):636-43.
87. Denizli A, Piskin E. Dye-ligand affinity systems. *J Biochem Biophys Methods* 2001;49(1-3):391-416.
88. Denizli A, Kokturk G, Yavuz H, Piskin E. Albumin adsorption from aqueous solutions and human plasma in a packed-bed column with Cibacron Blue F3GA-Zn(II) attached poly(EGDMA-HEMA) microbeads. *React Funct Polym* 1999;40(3):195-203. doi: 10.1016/S1381-5148(98)00043-1
89. Zhang S, Sun Y. Further studies on the contribution of electrostatic and hydrophobic interactions to protein adsorption on dye-ligand adsorbents. *Biotechnol Bioeng* 2001;75(6):710-7. doi: 10.1002/bit.10067
90. Hanggi D, Carr P. Analytical evaluation of the purity of commercial preparations of cibacron blue F3GA and related dyes. *Anal Biochem* 1985;149(1):91-104.
91. Akgöl S, Tüzmen N, Denizli A. Porous dye affinity beads for albumin separation from human plasma. *J Appl Polym Sci* 2007;105(3):1251-60. doi: 10.1002/app.26178
92. McLoughlin SB, Lowe CR. Applications of triazinyl dyes in protein purification. *Rev Prog Color Relat Top* 1988;18(1):16-28. doi: 10.1111/j.1478-4408.1988.tb00063.x
93. Tong XD, Sun Y. Agar-based magnetic affinity support for protein adsorption. *Biotechnol Prog* 2001;17(4):738-43. doi: 10.1021/bp010054s
94. Ma ZY, Guan YP, Lu HZ. Affinity adsorption of albumin on cibacron blue F3GA-coupled non-

- porous micrometer-sized magnetic polymer microspheres. *React Funct Polym* 2006;66(6):618-24. doi: 10.1016/j.reactfunctpolym.2005.10.014
95. Wolman FJ, Grasselli M, Smolko EE, Cascone O. Preparation and characterisation of Cibacron Blue F3G-A poly(ethylene) hollow-fibre affinity membranes. *Biotechnol Lett* 2000;22(17):1407-11. doi: 10.1023/A:1005664932413
 96. Jin G, Zhang L, Yao Q. Novel method for human serum albumin adsorption/separation from aqueous solutions and human plasma with Cibacron Blue F3GA-Zn(II) attached microporous affinity membranous capillaries. *J Membr Sci* 2007;287(2):271-9. doi: 10.1016/j.memsci.2006.10.047
 97. Qu F, Guan Y, Ma Z, Zhang Q. Synthesis of cibacron blue F3GA-coupled magnetic pmma nanospheres and their use for protein affinity separation. *Polym Int* 2009;58(8):888-92. doi: 10.1002/pi.2607
 98. Miyauchi M, Miao J, Simmons TJ, Dordick JS, Linhardt RJ. Flexible electrospun cellulose fibers as an affinity packing material for the separation of bovine serum albumin. *J Chromatogr Sep Tech* 2011;2(2). doi: 10.4172/2157-7064.1000110
 99. Wolman FJ, Smolko EE, Cascone O, Grasselli M. Improved hollow-fibre membranes for dye-affinity chromatography. *J Sep Sci* 2005;28(1):45-51. doi: 10.1002/jssc.200401915
 100. Denizli A, Tuncel A, Kozluca A, Ecevit K, Piskin E. Cibacron Blue F3G-A Attached Poly(Vinyl Alcohol) Particles for Specific Albumin Adsorption. *Sep Sci Technol* 1997;32(5):1003-15. doi: 10.1080/01496399708000942
 101. Denizli A, Salih B, Kozluca A, Piskin E. Comparison of albumin binding capacities of three different reactive dye-derivatized poly(ethylene glycol dimethacrylate-hydroxyethyl methacrylate) microbeads. *J Biomater Sci Polym Ed* 1997;8(6):411-20.
 102. Denizli A, Salih B, Kavakli C, Piskin E. Dye-incorporated poly(egdma-hema) microspheres as specific sorbents for aluminum removal. *J Chromatogr B Biomed Sci Appl* 1997;698(1-2):89-96.
 103. Yavuz H, Duru E, Genc O, Denizli A. Cibacron blue f3ga incorporated poly(methylmethacrylate) beads for albumin adsorption in batch system. *Colloids Surf Physicochem Eng Aspects* 2003;223(1-3):185-93. doi: 10.1016/S0927-7757(03)00153-5
 104. Odabaşı M, Denizli A. Cibacron Blue F3GA-attached magnetic poly(2-hydroxyethyl methacrylate) beads for human serum albumin adsorption. *Polym Int* 2004;53(3):332-8. doi: 10.1002/pi.1305
 105. Yavuz H, Denizli A. Dye affinity hollow fibers for albumin purification. *Macromol Biosci* 2004;4(2):84-91. doi: 10.1002/mabi.200300040
 106. Zhang J, Zhang ZP, Song Y, Cal H. Bovine serum albumin (BSA) adsorption with Cibacron Blue F3GA attached chitosan microspheres. *React Funct Polym* 2006;66(9):916-23. doi: 10.1016/j.reactfunctpolym.2005.12.003
 107. Demiryas N, Tüzmen N, Galaev IY, Pişkin E, Denizli A. Poly(acrylamide-allyl glycidyl ether) cryogel as a novel stationary phase in dye-affinity chromatography. *J Appl Polym Sci* 2007;105(4):1808-16. doi: 10.1002/app.26187
 108. Uzun L, Yavuz H, Say R, Ersoz A, Denizli A. Poly(ethylene dimethacrylate-glycidyl methacrylate) monolith as a stationary phase in dye-affinity chromatography. *Ind Eng Chem Res* 2004;43(20):6507-13. doi: 10.1021/ie040045z
 109. McCreath GE, Chase HA, Lowe CR. Novel affinity separations based on perfluorocarbon emulsions: Use of a perfluorocarbon affinity emulsion for the direct extraction of glucose-6-phosphate dehydrogenase from homogenised bakers' yeast. *J Chromatogr A* 1994;659(2):275-87. doi: 10.1016/0021-9673(94)85069-0
 110. Zhu J, Yang J, Sun G. Cibacron Blue F3GA functionalized poly(vinyl alcohol-co-ethylene) (PVA-co-PE) nanofibrous membranes as high efficient affinity adsorption materials. *J Membr Sci* 2011;385-386:269-76. doi: 10.1016/j.memsci.2011.10.001
 111. Uzun L, Odabaşı M, Arica Y, Denizli A. Poly(styrene-hydroxyethyl methacrylate) monodisperse microspheres as specific sorbent in dye affinity adsorption of albumin. *Sep Sci Technol* 2005;39(10):2401-18. doi: 10.1081/ss-120035934
 112. Odaba M, Garipcan B, Dede S, Denizli A. Methacrylamidohistidine in affinity ligands for immobilized metal-ion affinity chromatography of human serum albumin. *Biotechnol Bioprocess Eng* 2001;6(6):402-9. doi: 10.1007/bf02932321
 113. Labrou N, Clonis YD. The affinity technology in downstream processing. *J Biotechnol* 1994;36(2):95-119.
 114. Labrou NE, Mazitsos K, Clonis YD. Dye-ligand and biomimetic affinity chromatography. In: Hage DS, editor. Handbook of affinity chromatography. New York: Marcel Dekker, Inc; 2005. P. 231-55.